Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 70/100

Altimmune to Participate at Two Upcoming Investor Conferences

Wednesday, November 6, 2024 1 min read
Key Takeaway: Altimmune, Inc. has announced its participation in two upcoming investor conferences: the Guggenheim Inaugural Healthcare Innovation Conference in Boston and the UBS Global Healthcare Conference in Rancho Palos Verdes. At these events, members of Altimmune's management team will engage in fireside chats and 1x1 meetings, offering insights into the company's innovative therapeutic developments. The company is particularly focused on its candidate pemvidutide, which targets obesity and metabolic disorders.

Conference Participation Details

UBS Global Healthcare Conference
Date: November 11, 2025
Time: 8:45 a.m. ET
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Altimmune's participation in upcoming investor conferences highlights its engagement with the financial community.
  • The company's focus on innovative biomedical solutions, like pemvidutide, showcases its commitment to addressing health issues.
  • The webcasting of the sessions allows broader access to stakeholders and potential investors.

Full Press Release Details

GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in the following investor conferences:
Guggenheim Inaugural Healthcare Innovation Conference (Boston, MA)
Monday, November 11, 2024
Fireside Chat at 11:30 a.m. Eastern Time
UBS Global Healthcare Conference (Rancho Palos Verdes, CA)
Wednesday, November 13, 2024
Available for 1x1 meetings
Fireside Chat at 9:30 a.m. Pacific Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
President and Chief Executive Officer
Inizio Evoke, Biotech
Danielle.cantey@inizioevoke.com
jweilman@burnsmc.com
This press release was published by a CLEAR® Verified individual.

Frequently Asked Questions

Where will Altimmune be presenting in November 2024?

Altimmune will present at the Guggenheim Conference in Boston and the UBS Conference in California.

What is pemvidutide developed by Altimmune?

Pemvidutide is a dual receptor agonist for treating obesity and MASH.

How can I access Altimmune's conference sessions?

The conference sessions will be available via webcast on Altimmune's website.

When is the Fireside Chat at the UBS Conference?

The Fireside Chat at the UBS Conference is scheduled for 9:30 a.m. Pacific Time.

What type of company is Altimmune?

Altimmune is a clinical-stage biopharmaceutical company focusing on peptide-based therapeutics.

Tags: ALT Viatris Investor Conferences Healthcare pemvidutide obesity biopharmaceuticals investor conferences
Last updated: Nov 6, 2024

Conference Timeline

Nov 11, 2025
UBS Global Healthcare Conference
8:45 AM ET • Fireside Chat
Nov 18, 2025
Jefferies Global Healthcare
11:30 AM GMT • London